Next-generation therapeutic solutions for age-related macular degeneration

Khrishen Cunnusamy, Rafael Ufret-Vincenty, Shusheng Wang

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Age-related macular degeneration (AMD) is the primary cause of irreversible blindness among the elderly in the western world. To date, no cure is available and the current anti-VEGF therapy has only shown limited efficacy in improving visual acuity in neovascular AMD. The etiology of AMD remains elusive but research over the past decade has uncovered characteristic features of the disease. These features include: oxidative stress and retinal pigment epithelial cell cytotoxicity; loss of macromolecular permeability and hydraulic conductivity in Bruch's membrane; inflammation; choroidal neovascularization and vascular leakage; and loss of neuroprotection. Recent breakthroughs in understanding the pathogenesis of AMD have spawned an array of novel therapeutic agents designed to address these hallmarks. Here we review the features of AMD and highlight the most promising therapeutic and diagnostic approaches based on the patents published from 2008 to 2011.

Original languageEnglish (US)
Pages (from-to)193-206
Number of pages14
JournalPharmaceutical patent analyst
Volume1
Issue number2
StatePublished - May 1 2012

Fingerprint

Macular Degeneration
Bruch Membrane
Therapeutics
Choroidal Neovascularization
Western World
Retinal Pigments
Patents
Blindness
Vascular Endothelial Growth Factor A
Visual Acuity
Blood Vessels
Permeability
Oxidative Stress
Epithelial Cells
Inflammation
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Next-generation therapeutic solutions for age-related macular degeneration. / Cunnusamy, Khrishen; Ufret-Vincenty, Rafael; Wang, Shusheng.

In: Pharmaceutical patent analyst, Vol. 1, No. 2, 01.05.2012, p. 193-206.

Research output: Contribution to journalArticle

@article{46fb2c1578ab42b5b52f1bd801d5de4a,
title = "Next-generation therapeutic solutions for age-related macular degeneration",
abstract = "Age-related macular degeneration (AMD) is the primary cause of irreversible blindness among the elderly in the western world. To date, no cure is available and the current anti-VEGF therapy has only shown limited efficacy in improving visual acuity in neovascular AMD. The etiology of AMD remains elusive but research over the past decade has uncovered characteristic features of the disease. These features include: oxidative stress and retinal pigment epithelial cell cytotoxicity; loss of macromolecular permeability and hydraulic conductivity in Bruch's membrane; inflammation; choroidal neovascularization and vascular leakage; and loss of neuroprotection. Recent breakthroughs in understanding the pathogenesis of AMD have spawned an array of novel therapeutic agents designed to address these hallmarks. Here we review the features of AMD and highlight the most promising therapeutic and diagnostic approaches based on the patents published from 2008 to 2011.",
author = "Khrishen Cunnusamy and Rafael Ufret-Vincenty and Shusheng Wang",
year = "2012",
month = "5",
day = "1",
language = "English (US)",
volume = "1",
pages = "193--206",
journal = "Pharmaceutical patent analyst",
issn = "2046-8954",
publisher = "Future Science",
number = "2",

}

TY - JOUR

T1 - Next-generation therapeutic solutions for age-related macular degeneration

AU - Cunnusamy, Khrishen

AU - Ufret-Vincenty, Rafael

AU - Wang, Shusheng

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Age-related macular degeneration (AMD) is the primary cause of irreversible blindness among the elderly in the western world. To date, no cure is available and the current anti-VEGF therapy has only shown limited efficacy in improving visual acuity in neovascular AMD. The etiology of AMD remains elusive but research over the past decade has uncovered characteristic features of the disease. These features include: oxidative stress and retinal pigment epithelial cell cytotoxicity; loss of macromolecular permeability and hydraulic conductivity in Bruch's membrane; inflammation; choroidal neovascularization and vascular leakage; and loss of neuroprotection. Recent breakthroughs in understanding the pathogenesis of AMD have spawned an array of novel therapeutic agents designed to address these hallmarks. Here we review the features of AMD and highlight the most promising therapeutic and diagnostic approaches based on the patents published from 2008 to 2011.

AB - Age-related macular degeneration (AMD) is the primary cause of irreversible blindness among the elderly in the western world. To date, no cure is available and the current anti-VEGF therapy has only shown limited efficacy in improving visual acuity in neovascular AMD. The etiology of AMD remains elusive but research over the past decade has uncovered characteristic features of the disease. These features include: oxidative stress and retinal pigment epithelial cell cytotoxicity; loss of macromolecular permeability and hydraulic conductivity in Bruch's membrane; inflammation; choroidal neovascularization and vascular leakage; and loss of neuroprotection. Recent breakthroughs in understanding the pathogenesis of AMD have spawned an array of novel therapeutic agents designed to address these hallmarks. Here we review the features of AMD and highlight the most promising therapeutic and diagnostic approaches based on the patents published from 2008 to 2011.

UR - http://www.scopus.com/inward/record.url?scp=84872711994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872711994&partnerID=8YFLogxK

M3 - Article

C2 - 24040506

AN - SCOPUS:84872711994

VL - 1

SP - 193

EP - 206

JO - Pharmaceutical patent analyst

JF - Pharmaceutical patent analyst

SN - 2046-8954

IS - 2

ER -